

INTRODUCTION	XIX
STUDY GOALS AND OBJECTIVES.....	XIX
REASONS FOR DOING THE STUDY	XIX
CONTRIBUTIONS OF THE STUDY AND FOR WHOM.....	XIX
SCOPE AND FORMAT	XX
METHODOLOGY AND INFORMATION SOURCES.....	XX
ANALYST CREDENTIALS.....	XXI
RELATED BCC REPORTS	XXI
BCC ONLINE SERVICES.....	XXII
DISCLAIMER	XXII
EXECUTIVE SUMMARY	XXIII
<i>SUMMARY TABLE U.S. SALES OF GASTROINTESTINAL PRESCRIPTION AND</i>	
<i>OTC DRUGS AT MANUFACTURERS' SALES LEVELS, THROUGH 2009</i>	
<i>(\$ MILLIONS).....</i>	<i>XXIV</i>
<i>SUMMARY FIGURE U.S. SALES OF GASTROINTESTINAL PRESCRIPTION AND</i>	
<i>OTC DRUGS AT MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS)</i>	<i>XXIV</i>
INDUSTRY OVERVIEW.....	1
STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL	
SYSTEM.....	1
INGESTION AND PROPULSION OF FOOD	2
Mouth.....	3
Pharynx.....	3
Esophagus	3
DIGESTION AND ABSORPTION	4
Mouth.....	4
Stomach.....	4
Small Intestines.....	5
Physiology of Digestion	5
ELIMINATION	6
Large Intestine	6
Large Intestine (Continued).....	7
LIVER, BILIARY TRACT AND PANCREAS	8
LIVER	8
BILIARY TRACT	8
Bilirubin Metabolism.....	9
PANCREAS	9
GASTROINTESTINAL TRACT DISORDERS	9
DYSPHAGIA	9
Dysphagia (Continued).....	10

ESOPHAGEAL AND ABDOMINAL PAIN.....	11
VOMITING.....	12
INTESTINAL GAS.....	12
CONSTIPATION.....	13
DIARRHEA.....	13
TABLE 1 CAUSES OF DIARRHEA.....	13
TABLE 1 (CONTINUED).....	14
GASTROINTESTINAL TRACT WALL DISORDERS.....	14
GASTRITIS.....	14
TABLE 2 COMMON CAUSES OF GASTRITIS.....	15
GASTROENTERITIS.....	16
PEPTIC ULCER DISEASE.....	17
Peptic Ulcer Disease (Continued).....	18
GASTRIC ULCERS.....	19
DUODENAL ULCERS.....	20
INFLAMMATORY BOWEL DISEASE.....	21
ULCERATIVE COLITIS.....	21
CROHN'S DISEASE.....	22
ENTEROCOLITIS.....	23
DIVERTICULAR DISEASE.....	23
GASTROINTESTINAL TRACT MOTILITY DISORDERS.....	24
IRRITABLE BOWEL SYNDROME.....	24
INTESTINAL OBSTRUCTION.....	24
GASTROINTESTINAL MALABSORPTION DISORDERS.....	25
CELIAC DISEASE.....	26
TROPICAL SPRUE.....	26
CANCERS OF THE GASTROINTESTINAL TRACT.....	27
ESOPHAGEAL CANCER.....	27
GASTRIC CANCER.....	27
Gastric Cancer (Continued).....	28
LIVER CANCER.....	29
PANCREATIC CANCER.....	29
SMALL INTESTINAL CANCER.....	30
COLONIC POLYPS AND COLON CANCER.....	31
DEMOGRAPHICS.....	32
TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS.....	32
TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, 2002-2030 (THOUSANDS).....	33
FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2002-2030 (THOUSANDS).....	34
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2002-2030 (%).....	34

PILL-SIZED VIDEO CAMERA	35
INSURANCE COVERAGE	35
USE OF CELEBREX FOR ULCERATIVE COLITIS	36
FAST-ACTING ACID PUMP ANTAGONISTS.....	36
RADIO FREQUENCY IDENTIFICATION TECHNOLOGY	37
BRANDED VS OTC PROTON PUMP INHIBITORS.....	37
PHARMACEUTICAL AND HEALTH CARE COSTS	38
Pharmaceutical and Health Care Costs (Continued).....	39
<i>TABLE 5 PATENT EXPIRATION FOR SELECTED PRESCRIPTION</i>	
<i>GASTROINTESTINAL DRUGS 2005-2013</i>	40
MAIL ORDER TRENDS	41
Mail Order Trends (Continued)	42
PRESCRIPTION PRODUCT SEGMENTS BY TYPE	43
ANTIDIARRHEALS	43
SYSTEMICALLY ACTING ANTIDIARRHEALS.....	44
OPIUM PRODUCTS	44
<i>TABLE 6 MARKETED ANTIDIARRHEAL PRODUCTS</i>	45
MARKET SIZE AND GROWTH.....	45
<i>TABLE 7 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIDIARRHEALS AT</i>	
<i>U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS)</i>	46
<i>FIGURE 3 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIDIARRHEALS AT</i>	
<i>U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS)</i>	46
COMPETITIVE STRUCTURE AND MARKET SHARE.....	46
<i>TABLE 8 U.S. PRESCRIPTION ANTIDIARRHEALS MANUFACTURERS' REVENUES</i>	
<i>AND MARKET SHARE, 2004 (\$ MILLIONS, %)</i>	47
<i>FIGURE 4 U.S. PRESCRIPTION ANTIDIARRHEALS MANUFACTURERS' MARKET</i>	
<i>SHARE, 2004 (%)</i>	47
ANTIEMETICS.....	47
LOCALLY ACTING ANTIEMETICS	48
CENTRALLY ACTING ANTIEMETICS.....	48
ANTIDOPAMINERGICS.....	48
Antidopaminergics (Continued)	49
ANTICHOLINERGICS	50
MISCELLANEOUS ANTIEMETICS	50
Miscellaneous Antiemetics (Continued)	51
<i>TABLE 9 MARKETED ANTIEMETIC PRODUCTS</i>	52
MARKET SIZE AND GROWTH.....	52
<i>TABLE 10 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIEMETICS AT U.S.</i>	
<i>MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS)</i>	53
<i>FIGURE 5 PRODUCT REVENUES OF U.S. PRESCRIPTION ANTIEMETICS AT U.S.</i>	
<i>MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS)</i>	53
COMPETITIVE STRUCTURE AND MARKET SHARE.....	53

TABLE 11 U.S. PRESCRIPTION ANTIEMETIC MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %)	54
FIGURE 6 U.S. PRESCRIPTION ANTIEMETICS MANUFACTURERS' MARKET SHARE, 2004 (%)	54
GASTROINTESTINAL CANCER TREATMENTS	55
GASTROINTESTINAL CANCER...(CONTINUED)	56
TABLE 12 MARKETED GASTROINTESTINAL CANCER PRODUCTS	57
MARKET SIZE AND GROWTH	57
TABLE 13 PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS)	58
FIGURE 7 PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS)	58
COMPETITIVE STRUCTURE AND MARKET SHARE	58
TABLE 14 U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %)	59
FIGURE 8 U.S. PRESCRIPTION GASTROINTESTINAL CANCER DRUGS MANUFACTURERS' MARKET SHARE, 2004 (%)	59
H2 INHIBITORS	60
H2 INHIBITORS (CONTINUED)	61
H2 INHIBITORS (CONTINUED)	62
TABLE 15 MARKETED H2 INHIBITORS PRODUCTS	63
MARKET SIZE AND GROWTH	63
TABLE 16 PRODUCT REVENUES OF U.S. PRESCRIPTION H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS)	63
FIGURE 9 PRODUCT REVENUES OF U.S. PRESCRIPTION H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS)	64
COMPETITIVE STRUCTURE AND MARKET SHARE	64
TABLE 17 U.S. PRESCRIPTION H2 INHIBITORS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %)	64
FIGURE 10 U.S. PRESCRIPTION H2 INHIBITORS MANUFACTURERS' MARKET SHARE, 2004 (%)	65
LAXATIVES	65
TABLE 18 MARKETED LAXATIVE PRODUCTS	66
MARKET SIZE AND GROWTH	67
TABLE 19 PRODUCT REVENUES OF U.S. PRESCRIPTION LAXATIVES AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS)	67
FIGURE 11 PRODUCT REVENUES OF U.S. PRESCRIPTION LAXATIVES AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS)	67
COMPETITIVE STRUCTURE AND MARKET SHARE	68
TABLE 20 U.S. PRESCRIPTION LAXATIVES MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %)	68
FIGURE 12 U.S. PRESCRIPTION LAXATIVES MANUFACTURERS' MARKET SHARE, 2004 (%)	68
PROTON PUMP INHIBITORS	69
PROTON PUMP INHIBITORS (CONTINUED)	70

TABLE 21	MARKETED PROTON PUMP INHIBITOR PRODUCTS.....	71
	MARKET SIZE AND GROWTH.....	71
TABLE 22	PRODUCT REVENUES OF U.S. PRESCRIPTION PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	72
FIGURE 13	PRODUCT REVENUES OF U.S. PRESCRIPTION PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	72
	COMPETITIVE STRUCTURE AND MARKET SHARE.....	72
TABLE 23	U.S. PRESCRIPTION PROTON PUMP INHIBITORS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %).....	73
FIGURE 14	U.S. PRESCRIPTION PROTON PUMP INHIBITORS MANUFACTURERS' MARKET SHARE, 2004 (%).....	73
	ANTI-INFLAMMATORY.....	74
TABLE 24	MARKETED INFLAMMATORY PRODUCTS.....	74
	MARKET SIZE AND GROWTH.....	75
TABLE 25	PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	75
FIGURE 15	PRODUCT REVENUES OF U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2002- 2009 (\$ MILLIONS).....	75
	COMPETITIVE STRUCTURE AND MARKET SHARE.....	76
TABLE 26	U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %).....	76
FIGURE 16	U.S. PRESCRIPTION GASTROINTESTINAL INFLAMMATORY AGENTS MANUFACTURERS' MARKET SHARE, 2004 (%).....	76
	OTHER GASTROINTESTINAL PRODUCTS.....	77
	ANTISPASMODICS.....	77
TABLE 27	MARKETED ANTISPASMODIC PRODUCTS.....	77
	DIGESTANTS.....	77
	GASTRIC ACIDIFIERS.....	78
	PANCREATIC ENZYMES.....	78
TABLE 28	MARKETED DIGESTANT PRODUCTS.....	78
	EVACUANTS.....	79
TABLE 29	MARKETED EVACUANTS PRODUCTS.....	79
	MUCOSAL PROTECTANTS.....	79
TABLE 30	MARKETED MUCOSAL PROTECTANT PRODUCTS.....	80
	PROSTAGLANDINS.....	80
TABLE 31	MARKETED PROSTAGLANDIN PRODUCTS.....	80
	STIMULANTS.....	81
TABLE 32	MARKETED STIMULANT PRODUCTS.....	81
	MARKET SIZE AND GROWTH.....	81
TABLE 33	PRODUCT REVENUES OF U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	82

FIGURE 17 PRODUCT REVENUES OF U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	82
COMPETITIVE STRUCTURE AND MARKET SHARE.....	82
TABLE 34 U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUG MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %).....	83
FIGURE 18 U.S. PRESCRIPTION OTHER GASTROINTESTINAL DRUG MANUFACTURERS' MARKET SHARE, 2004 (%).....	83
TOTAL U.S. PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH.....	84
TABLE 35 MARKET SIZE OF U.S. PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT MARKETS BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	84
FIGURE 19 MARKET SIZE OF U.S. PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT MARKET BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	85
TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS.....	85
TABLE 36 TOTAL MANUFACTURERS SALES AND MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2004 (\$ MILLIONS).....	86
FIGURE 20 MANUFACTURERS MARKET SHARE OF TOTAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2004 (%).....	87
OTC PRODUCT SEGMENTS BY TYPE.....	88
ANTACIDS.....	88
SYSTEMIC ANTACIDS.....	89
Sodium Bicarbonate.....	89
NONSYSTEMIC ANTACIDS.....	89
Calcium Carbonate.....	89
Aluminum Products.....	90
Magnesium Products.....	90
Combination Products.....	91
TABLE 37 MARKETED OTC ANTACID PRODUCTS.....	91
TABLE 37 (CONTINUED).....	92
MARKET SIZE AND GROWTH.....	92
TABLE 38 PRODUCT REVENUES OF U.S. OTC ANTACIDS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	92
FIGURE 21 PRODUCT REVENUES OF U.S. OTC ANTACIDS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	93
COMPETITIVE STRUCTURE AND MARKET SHARE.....	93
TABLE 39 U.S. OTC ANTACID MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %).....	94
FIGURE 22 U.S. OTC ANTACID MANUFACTURERS' MARKET SHARE, 2004 (%).....	94
LOCALLY ACTING ANTIDIARRHEALS.....	94

ADSORBENTS	95
INTESTINAL FLORA MODIFIERS	96
TABLE 40 MARKETED OTC ANTIDIARRHEAL PRODUCTS	96
MARKET SIZE AND GROWTH	96
TABLE 41 PRODUCT REVENUES OF U.S. OTC ANTIDIARRHEALS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	97
FIGURE 23 PRODUCT REVENUES OF U.S. OTC ANTIDIARRHEALS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	97
COMPETITIVE STRUCTURE AND MARKET SHARE.....	97
TABLE 42 U.S. OTC ANTIDIARRHEALS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %).....	98
FIGURE 24 U.S. OTC ANTIDIARRHEALS MANUFACTURERS' MARKET SHARE, 2004 (%).....	98
H2 INHIBITORS.....	99
H2 INHIBITORS (CONTINUED)	100
H2 INHIBITORS (CONTINUED)	101
TABLE 43 MARKETED OTC H2 INHIBITORS PRODUCTS	102
MARKET SIZE AND GROWTH.....	102
TABLE 44 PRODUCT REVENUES OF U.S. OTC H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	102
FIGURE 25 PRODUCT REVENUES OF U.S. OTC H2 INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	103
COMPETITIVE STRUCTURE AND MARKET SHARE.....	103
TABLE 45 U.S. OTC H2 INHIBITOR MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %)	104
FIGURE 26 U.S. OTC H2 INHIBITOR MANUFACTURERS' MARKET SHARE, 2004 (%).....	104
PROTON PUMP INHIBITORS.....	104
OMEPRAZOLE (PRILOSEC, PROCTOR & GAMBLE).....	104
TABLE 46 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS	105
MARKET SIZE AND GROWTH.....	105
TABLE 47 PRODUCT REVENUES OF U.S. OTC PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	106
FIGURE 27 PRODUCT REVENUES OF U.S. OTC PROTON PUMP INHIBITORS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	106
COMPETITIVE STRUCTURE AND MARKET SHARE.....	106
TABLE 48 U.S. OTC PROTON PUMP INHIBITOR MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %).....	107
OTHER OTC GASTROINTESTINAL PRODUCTS	107
ANTIEMETICS	107
Locally Acting Antiemetics	107
Centrally Acting Antiemetics.....	108
TABLE 49 MARKETED OTC ANTIEMETICS PRODUCTS	108
EMETICS	108
TABLE 50 MARKETED OTC EMETIC PRODUCTS	109
ANTIFLATULENCE PRODUCTS	109

TABLE 51 MARKETED OTC ANTIFLATULENCE PRODUCTS.....	109
TABLE 51 (CONTINUED)	110
LAXATIVES	110
TABLE 52 MARKETED OTC LAXATIVE PRODUCTS	111
MARKET SIZE AND GROWTH.....	111
TABLE 53 PRODUCT REVENUES OF U.S. OTC OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	111
FIGURE 28 PRODUCT REVENUES OF U.S. OTC OTHER GASTROINTESTINAL DRUGS AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	112
COMPETITIVE STRUCTURE AND MARKET SHARE.....	112
TABLE 54 U.S. OTC OTHER GASTROINTESTINAL DRUGS MANUFACTURERS' REVENUES AND MARKET SHARE, 2004 (\$ MILLIONS, %)	112
FIGURE 29 U.S. OTC OTHER GASTROINTESTINAL DRUGS MANUFACTURERS' MARKET SHARE, 2004 (%)	113
TOTAL U.S. OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH	113
TABLE 55 MARKET SIZE OF U.S. GASTROINTESTINAL DISORDER TREATMENT MARKET BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2009 (\$ MILLIONS).....	113
FIGURE 30 MARKET SIZE OF U.S. GASTROINTESTINAL DISORDER TREATMENT MARKET BY TYPE AT U.S. MANUFACTURERS' SALES LEVELS, 2002-2009 (\$ MILLIONS).....	114
TOTAL U.S. OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS	114
TABLE 56 MANUFACTURERS MARKET SHARE OF TOTAL OTC GASTROINTESTINAL DISORDER TREATMENTS AT U.S. MANUFACTURERS' SALES LEVELS, 2004 (\$ MILLIONS, %)	115
FIGURE 31 TOTAL MANUFACTURERS MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS BY REVENUES AT U.S. MANUFACTURERS' SALES LEVELS, 2004 (%).....	115
RESEARCH AND DEVELOPMENT	116
CALMACTIN	116
CANASA	116
ENTEREG	116
PTK787	117
RAPINEX.....	117
TYSABRI	117
ALICAFORSEN.....	118
CDP-870.....	118
CDP-870 (Continued)	119
METHYLNALTREXONE (MNTX).....	120
OPC-6535.....	120
ORBEC.....	120
SUCAMPO.....	121

RENZAPRIDE.....	121
683699.....	121
ABT-224.....	122
ALICAFORSEN ENEMA.....	122
DEXTOFISOPAM.....	122
EKB-569.....	122
GTI-2040.....	122
PUMOSETRAG.....	123
RDP-58.....	123
SORAPRAZAN.....	123
SUTENT.....	123
TALNETANT.....	124
BL-1030.....	124
BL-1050.....	124
<i>TABLE 57 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT.....</i>	<i>124</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>125</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>126</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>127</i>
INDUSTRY PARTICIPANTS BY PRODUCT TYPE.....	128
<i>TABLE 58 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS BY</i>	
<i>TYPE, 2004.....</i>	<i>128</i>
COMPANY PROFILES.....	129
ASTRAZENECA.....	129
History.....	129
AXCAN PHARMA INC.....	130
History.....	130
CENTOCOR INC.....	131
History.....	131
EISAI INC.....	132
History.....	132
GENENTECH INC.....	132
History.....	133
GLAXOSMITHKLINE.....	133
GlaxoSmithKline (Continued).....	134
GlaxoSmithKline (Continued).....	135
History.....	136
JOHNSON & JOHNSON.....	136
History.....	137
MCNEIL CONSUMER HEALTHCARE.....	137
History.....	137
MERCK & COMPANY INC.....	138

History.....	138
NOVARTIS INTERNATIONAL AG.....	139
History.....	139
PFIZER INC.	140
History.....	140
PROCTER & GAMBLE COMPANY.....	141
History.....	141
ROCHE	142
History.....	142
SANOFI-AVENTIS	142
History.....	143
SOLVAY PHARMACEUTICALS	143
History.....	144
TAP PHARMACEUTICALS PRODUCTS INC.....	144
History.....	144
WYETH.....	145
History.....	146
APPENDIX	147
COMPANY DIRECTORY	147
3M CORPORATION.....	147
ABBOTT LABORATORIES.....	147
ACAMBIS PLC.....	147
ADERIS PHARMACEUTICALS (DISCOVERY THERAPEUTICS)	147
ADOLOR CORPORATION	147
ALIZYME PLC	148
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.	148
ALTANA PHARMA AG	148
AMARIN CORPORATION	148
APOTHECON B.V.....	148
ARCO PHARMACEUTICALS.....	149
ASTRAZENECA PLC.....	149
AXCAN PHARMA INC.	149
BERLEX LABORATORIES INC.	149
BERTEK (MYLAN LABORATORIES INC.).....	149
BIOGEN IDEC INC.	149
BIOLINERX LTD.....	150
BIOPORT CORPORATION	150
BRAINTREE LABORATORIES INC.	150
BRISTOL-MYERS SQUIBB COMPANY	150

CENTOCOR, INC.....	150
CHEMOCENTRYX INC.	150
CYTOKINE PHARMASCIENCES INC.	151
DOR BIOPHARMA INC.	151
EISAI CO., LTD.	151
ELAN CORPORATION PLC	151
ELKINS-SINN INC.....	151
FIRST HORIZON CORPORATION	151
GENAERA CORPORATION	152
GENENTECH INC.	152
GENZYME GENERAL	152
GLAXOSMITHKLINE PLC	152
GLAXOSMITHKLINE CONSUMER HEALTHCARE	152
HOFFMAN-LAROCHE LTD. (ROCHE)	152
IMMUCELL CORPORATION.....	153
INKINE PHARMACEUTICAL COMPANY INC.....	153
ISIS PHARMACEUTICALS INC.	153
IVAX CORPORATION.....	153
JANSSEN PHARMACEUTICA PRODUCTS L.P. (JOHNSON & JOHNSON).....	153
JOHNSON & JOHNSON.....	153
LORUS THERAPEUTICS INC.	154
MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS	154
MEDISCA INC.	154
MERCK & CO., INC.....	154
MERIDIAN GROUP INTERNATIONAL INC.....	154
MONARCH LABS	154
NABI BIOPHARMACEUTICALS	155
NOVARTIS CORPORATION	155
NPS PHARMACEUTICALS INC.	155
OTSUKA AMERICA PHARMACEUTICAL INC.	155
PERRIGO COMPANY	155
PFIZER INC. (SEARLE).....	155
THE PROCTER & GAMBLE COMPANY.....	156
PRODIGENE INC.	156
PROGENICS PHARMACEUTICALS INC.	156
PROTEIN DESIGN LABS INC.	156
RAVEN BIOTECHNOLOGIES INC.	156
RELIANT PHARMACEUTICALS INC.....	156
ROXANE LABORATORIES INC.	157
SALIX PHARMACEUTICALS LTD.....	157

SANOFI-AVENTIS	157
SANTARUS INC.	157
SCHERING AG	157
SCHWARZ PHARMA AG	157
SERONO S.A.	158
SHIRE PHARMACEUTICALS GROUP PLC	158
SOLVAY S.A.	158
SUCAMPO PHARMACEUTICALS INC.	158
SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC)	158
TANOX INC.	158
TAP PHARMACEUTICAL PRODUCTS INC.	159
TARGACEPT INC.	159
THERAVANCE INC.	159
UCB PHARMA INC.	159
UNIMED PHARMACEUTICALS INC.	159
VELA PHARMACEUTICALS INC.	159
WATSON PHARMACEUTICALS, INC.	160
WYETH (WHITEHALL-ROBINS HEALTHCARE INC.)	160
XOMA LTD.	160
YAMANOUCHI PHARMA LTD.	160